High Risk, High Reward for the Magnificent Seven High Expectations for Earnings Season The Roundhill Magnificent Seven ETF (MAGS) climbed 15.2% in... Read More →
In-Network Stocks for OZEM Originally developed for diabetes treatment, the discovery of GLP-1 therapeutics as a weight loss... Read More →
Roundhill Roundup - The “Winner Takes All” Market With major indexes hitting all-time high after all-time high, you would think investors would be... Read More →
A Response to "There Is No Magnificent Seven" On June 14, 2024, Allan Sloan published a commentary in Barron’s with the headline “There Is No... Read More →
Roundhill Roundup: Markets Go Up Last year, a knock on the market was its lack of breadth, whereby a small number of names were... Read More →
Digging Deeper: Return of Capital Distributions in ETFs In our previous blog we discussed the basics of ETF distributions, including how amounts are... Read More →
How to Invest in Weight Loss Drugs: The Complete Beginners Guide A recent report from the Centers for Disease Control and Prevention (CDC) at the end of 2023... Read More →
Introducing OZEM: The GLP-1 Skinny Addressing the Obesity Epidemic The global obesity epidemic has reached alarming proportions. Since... Read More →
Behind the Curtain: ETF Distributions Most ETFs are structured as Regulated Investment Companies, commonly referred to as RICs. As RICs,... Read More →